FDA Committee Reviews Otsuka and Lundbeck’s PTSD Treatment Application

The latest announcement is out from Otsuka Holdings Co ( (JP:4578) ).

Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S have announced that the FDA’s Psychopharmacologic Drugs Advisory Committee has reviewed their supplemental New Drug Application for REXULTI (brexpiprazole) in combination with sertraline for treating PTSD in adults. The committee voted against the efficacy of this combination, which may impact the approval process and the companies’ market positioning in PTSD treatment.

The most recent analyst rating on (JP:4578) stock is a Buy with a Yen10400.00 price target. To see the full list of analyst forecasts on Otsuka Holdings Co stock, see the JP:4578 Stock Forecast page.

More about Otsuka Holdings Co

Otsuka Holdings Co., Ltd. operates in the pharmaceutical industry, focusing on the development and marketing of innovative healthcare products. The company is known for its work in mental health and central nervous system disorders, with a strong market presence in Japan and globally.

YTD Price Performance: -22.82%

Average Trading Volume: 1,388,601

Technical Sentiment Signal: Hold

Current Market Cap: Yen3471.8B

See more insights into 4578 stock on TipRanks’ Stock Analysis page.